|
The HRT market is developing fast. There is increasing awareness that HRT is very effective and restores the
quality of life of many women suffering from menopausal complaints. Long-term HRT reduces their risks for future osteoporosis and
cardiovascular disease.
The new oral HRT combination preparation femoston®, first launched in
1995, will give Solvay Pharmaceuticals presence in HRT another boost. femoston®
is the only HRT product that contains dydrogesterone - by many regarded as an ideal progestogen for HRT - combined with 17ß -estradiol,
which is identical to a woman's most important natural estrogen. The combination of these hormones within one tablet, is a unique aspect of femoston®.
The Solvay HRT portfolio will be further enriched, by new products and presentation forms that are currently in the pipeline.
duphaston® The Leading Progestogen
A perfect example of high-quality progestogen is Solvay's duphaston®
(dydrogesterone), the most prescribed progestogen in Western Europe and Middle East area. The unique production process of this synthetic progestogen with
pure progestogenic effects requires high standards of production technology.
Supporting The European And North American Menopause Society
The European Menopause Society (EMS) and the North American Menopause Society (NAMS) are non-profit
scientific associations, founded with the mission to coordinate the medical and socio-economic use of the results of scientific
studies on the menopause. Solvay Pharmaceuticals is one of the original sponsors of both EMS and NAMS. They are supporting the
European Society in its tasks of creating synergy by pooling the experiences of the National Societies and spreading knowledge about the menopause.
 Related Links
|